New drug candidate B-OT takes first step in human safety trial
NCT ID NCT07450833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and tolerability of an experimental drug called Benfo-Oxythiamine (B-OT) in 48 healthy male volunteers. Researchers gave the drug as single or multiple daily doses and monitored participants closely for side effects, blood levels, and lab changes. The goal was to see if B-OT is safe enough to study further for possible use against infectious diseases and cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Benfo-oxythiamine (B-OT)
What this could lead to
If this drug proves safe, it could pave the way for future studies testing B-OT as a treatment for infectious diseases or cancer.
What could go wrong
This is a very early Phase 1 trial in only 48 healthy volunteers. It only looks at safety and how the drug moves through the body, not whether it works against any disease. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Diagnostics and Consultation Center (DCC) Convex EOOD
Sofia, Bulgaria